MARKET

MTEM

MTEM

Molecular US
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.86
-0.48
-5.76%
After Hours: 7.86 0 0.00% 17:31 05/14 EDT
OPEN
7.98
PREV CLOSE
8.34
HIGH
8.09
LOW
7.68
VOLUME
438.25K
TURNOVER
--
52 WEEK HIGH
17.99
52 WEEK LOW
7.51
MARKET CAP
440.85M
P/E (TTM)
-3.5598
1D
5D
1M
3M
1Y
5Y
Molecular Templates Inc. (MTEM) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com · 22h ago
BRIEF-Molecular Templates, Inc. Reports First Quarter 2021 Financial Results
reuters.com · 1d ago
Molecular Templates EPS beats by $0.26, misses on revenue
Molecular Templates (MTEM): Q1 GAAP EPS of $0.51 beats by $0.26.Revenue of $3.22M (-22.2% Y/Y) misses by $31.93M.Press Release
Seekingalpha · 1d ago
-- Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q1 Revenue $3.2M
MT Newswires · 1d ago
DGAP-News: BB BIOTECH AG: Successful vaccination campaigns point the way out of the corona crisis - sector re-valuation used for portfolio investments
EQS Group AG · 04/23 05:01
Molecular Templates has a ‘unique’ platform in oncology: BofA
Molecular Templates ([[MTEM]] +9.5%) has posted its best one-day gain since December after Bank of America initiated the coverage on the stock with a buy rating and a price target
Seekingalpha · 04/21 20:08
Intuitive Surgical upgraded after earnings beat; Oppenheimer sizes up new Vertex – CRISPR deal, and more in today’s analyst action
Today’s analyst action includes Intuitive Surgical upgrade at Baird after better-than-expected Q1 earnings and positive catalyst watches opened at Citi on Abbvie and Bristol-Myers Squibb.Intuitive Surgical extends gains as Oppenheimer
Seekingalpha · 04/21 12:25
--BofA Securities Starts Molecular Templates at Buy with $12 Price Target
MT Newswires · 04/21 11:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MTEM. Analyze the recent business situations of Molecular US through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average MTEM stock price target is 15.75 with a high estimate of 22.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 33.25M
% Owned: 59.27%
Shares Outstanding: 56.09M
TypeInstitutionsShares
Increased
12
2.67M
New
3
45.51K
Decreased
13
126.46K
Sold Out
3
41.76K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Director
Harold Selick
President/Chief Operating Officer
Jason Kim
Chief Executive Officer/Chief Scientific Officer/Director
Eric Poma
Chief Financial Officer/Treasurer/Secretary
Adam Cutler
Other
Roger Waltzman
Independent Director
David Hirsch
Independent Director
David Hoffmann
Independent Director
Kevin Lalande
Independent Director
Jonathan Lanfear
Independent Director
Scott Morenstein
Independent Director
Corazon Sanders
No Data
  • All
  • Financials
  • Insiders
More
About MTEM
Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.

Webull offers kinds of Molecular Templates Inc stock information, including NASDAQ:MTEM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTEM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTEM stock methods without spending real money on the virtual paper trading platform.